Joel Gelernter
Overview
Explore the profile of Joel Gelernter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
532
Citations
17709
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peng P, Hao Y, Zhang X, Ma Y, Liu X, Shen D, et al.
Ann Gen Psychiatry
. 2025 Mar;
24(1):12.
PMID: 40033412
Background: This study sought to investigate the prevalence, correlates, and network structure of the manifested symptoms in gambling disorder (GD) among methamphetamine (MA) use disorder (MUD) patients in China. Methods:...
2.
Johnson E, Lai D, Miller A, Hatoum A, Deak J, Balbona J, et al.
medRxiv
. 2025 Feb;
PMID: 39974067
Genetic research on nicotine dependence has utilized multiple assessments that are in weak agreement. We conducted a genome-wide association study of nicotine dependence defined using the Diagnostic and Statistical Manual...
3.
Wang L, Kranzler H, Gelernter J, Zhou H
Biol Psychiatry
. 2025 Feb;
PMID: 39892688
Background: Alcohol use disorder (AUD) is a leading cause of death and disability worldwide. There has been substantial progress in identifying genetic variants underlying AUD. However, whole-exome sequencing (WES) studies...
4.
Huang Y, Kurniansyah N, Levey D, Gelernter J, Huffman J, Cho K, et al.
medRxiv
. 2025 Jan;
PMID: 39802770
Strong sex differences exist in sleep phenotypes and also cardiovascular diseases (CVDs). However, sex-specific causal effects of sleep phenotypes on CVD-related outcomes have not been thoroughly examined. Mendelian randomization (MR)...
5.
Davis C, Jinwala Z, Hatoum A, Toikumo S, Agrawal A, Rentsch C, et al.
JAMA Netw Open
. 2025 Jan;
8(1):e2453913.
PMID: 39786773
Importance: Recently, the US Food and Drug Administration gave premarketing approval to an algorithm based on its purported ability to identify individuals at genetic risk for opioid use disorder (OUD)....
6.
Javidnia S, Roe J, Karhunen V, Gill D, Bell S, Deak J, et al.
medRxiv
. 2025 Jan;
PMID: 39763526
Background: The long-term impact of opioid use disorder (OUD) on brain health has been little explored although of potentially high public health importance. Objectives: To investigate the potential causal impact...
7.
Moo-Choy A, Stein M, Gelernter J, Wendt F
Can J Psychiatry
. 2024 Dec;
70(2):117-126.
PMID: 39654303
Objective: Posttraumatic stress disorder (PTSD) affects 3.9%-5.6% of the worldwide population, with well-documented sex-related differences. While psychosocial and hormonal factors affecting sex differences in PTSD and posttraumatic stress (PTS) symptom...
8.
Linner R, Mallard T, Barr P, Sanchez-Roige S, Madole J, Driver M, et al.
Nat Neurosci
. 2024 Dec;
28(1):213.
PMID: 39643700
No abstract available.
9.
Jinwala Z, Green R, Khan Y, Gelernter J, Kember R, Hartwell E
medRxiv
. 2024 Nov;
PMID: 39606347
Background: Few individuals with alcohol use disorder (AUD) receive treatment. Previous studies have shown drinking behavior, psychological problems, and substance dependence to predict treatment seeking. However, to date, no studies...
10.
Braun A, Shekhar S, Levey D, Straub P, Kraft J, Panagiotaropoulou G, et al.
Nat Commun
. 2024 Nov;
15(1):9839.
PMID: 39537604
Myasthenia gravis (MG) is a rare autoantibody-mediated disease affecting the neuromuscular junction. We performed a genome-wide association study of 5708 MG cases and 432,028 controls of European ancestry and a...